Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry M Wall

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Clinical Journal of the American Society of Nephrology : CJASN|April 23, 2016
Age and Outcomes Associated with BP in Patients with Incident CKDCsaba P Kovesdy, Ahmed Alrifai, Elvira O Gosmanova, et al.
The American Journal of Medicine|April 25, 2020
Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis MortalityElvira O Gosmanova, Miklos Z Molnar, Adnan Naseer, et al.
Kidney International Reports|August 1, 2017
<i>APOL1</i> renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention TrialBarry I Freedman, Michael V Rocco, Jeffrey T Bates, et al.
European Heart Journal|July 2, 2019
Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trialPranav S Garimella, Alexandra K Lee, Walter T Ambrosius, et al.
American Journal of Nephrology|August 12, 2016
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration DefinitionsMichael V Rocco, Arlene Chapman, Glenn M Chertow, et al.
Journal of the American Society of Hypertension : JASH|September 1, 2015
Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention TrialCarolyn H Still, Timothy E Craven, Barry I Freedman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 15, 2018
PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINTCharles Ginsberg, Timothy E Craven, Michel B Chonchol, et al.
American Journal of Hypertension|October 7, 2017
Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical TrialCarolyn H Still, Carlos J Rodriguez, Jackson T Wright, et al.
Kidney International|July 3, 2019
The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injuryAlexander L Bullen, Ronit Katz, Alexandra K Lee, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 23, 2017
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)Michael V Rocco, Kaycee M Sink, Laura C Lovato, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Clinical Journal of the American Society of Nephrology : CJASN|April 23, 2016
Age and Outcomes Associated with BP in Patients with Incident CKDCsaba P Kovesdy, Ahmed Alrifai, Elvira O Gosmanova, et al.
The American Journal of Medicine|April 25, 2020
Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis MortalityElvira O Gosmanova, Miklos Z Molnar, Adnan Naseer, et al.
Kidney International Reports|August 1, 2017
<i>APOL1</i> renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention TrialBarry I Freedman, Michael V Rocco, Jeffrey T Bates, et al.
European Heart Journal|July 2, 2019
Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trialPranav S Garimella, Alexandra K Lee, Walter T Ambrosius, et al.
American Journal of Nephrology|August 12, 2016
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration DefinitionsMichael V Rocco, Arlene Chapman, Glenn M Chertow, et al.
Journal of the American Society of Hypertension : JASH|September 1, 2015
Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention TrialCarolyn H Still, Timothy E Craven, Barry I Freedman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 15, 2018
PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINTCharles Ginsberg, Timothy E Craven, Michel B Chonchol, et al.
American Journal of Hypertension|October 7, 2017
Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical TrialCarolyn H Still, Carlos J Rodriguez, Jackson T Wright, et al.
Kidney International|July 3, 2019
The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injuryAlexander L Bullen, Ronit Katz, Alexandra K Lee, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 23, 2017
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)Michael V Rocco, Kaycee M Sink, Laura C Lovato, et al.
Pageof 7